Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

FULC

Fulcrum Therapeutics Inc

3.54

Jul 13 • 04:00PM ET +0.04 (1.14%)

3.51

Aftermarket • 07:59PM ET -0.03 (-0.81%)

Healthcare Biotechnology USA Micro NASD

Peers: INCY BMRN VKTX KRYS KYMR NUVL RYTM AXSM MDGL NBIX

| Held by: VTI IWM VXF XPH VTWO IWN IBB FESM VHT SCHA

Scroll to Statements

Index	RUT
Market Cap	235.88M
Enterprise Value	-91.57M
Income	-76.12M
Sales	0.00M
Book/sh	5.00
Cash/sh	5.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	55
IPO	Jul 18, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.71
P/C	0.71
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	34.33
Current Ratio	34.33
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-1.15
EPS next Y	-0.67
EPS next Q	-0.22
EPS this Y	33.72%
EPS next Y	14.08%
EPS next 5Y	18.03%
EPS past 3/5Y	21.49% 15.80%
Sales past 3/5Y	- -
EPS Y/Y TTM	-2365.81%
Sales Y/Y TTM	-100.00%
EPS Q/Q	12.28%
Sales Q/Q	-
Earnings	Apr 27 BMO
EPS/Sales Surpr.	15.05% -

Insider Own	15.30%
Insider Trans	-0.32%
Inst Own	110.74%
Inst Trans	14.25%
ROA	-25.83%
ROE	-27.10%
ROIC	-22.61%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-3.19%
SMA50	-29.29%
SMA200	-57.53%
Trades

Shs Outstand	66.61M
Shs Float	56.44M
Short Float	11.38%
Short Ratio	2.71
Short Interest	6.43M
52W High	15.74 -77.51%
52W Low	2.83 25.09%
Volatility	5.16% 5.91%
ATR (14)	0.27
RSI (14)	36.12
Beta	3.04
Rel Volume	0.73
Avg Volume	2.37M
Volume	1,721,383

Perf Week	-4.84%
Perf Month	0.85%
Perf Quarter	-53.11%
Perf Half Y	-64.99%
Perf YTD	-68.70%
Perf Year	-54.79%
Perf 3Y	-4.84%
Perf 5Y	-64.46%
Perf 10Y	-
Recom	3.12
Target Price	3.40
Prev Close	3.50
Price	3.54
Change	1.14%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-03-26	Downgrade	JP Morgan	Overweight → Underweight
Jun-02-26	Downgrade	Truist	Buy → Hold	$4
Jun-02-26	Downgrade	Stifel	Buy → Hold	$3
Jun-02-26	Downgrade	Piper Sandler	Overweight → Neutral	$3
Jun-02-26	Downgrade	Leerink Partners	Outperform → Market Perform	$4
Jun-02-26	Downgrade	H.C. Wainwright	Buy → Neutral	$3
Jan-12-26	Initiated	JP Morgan	Overweight	$20
Nov-24-25	Initiated	Truist	Buy
Jul-29-25	Upgrade	H.C. Wainwright	Neutral → Buy	$4 → $12
May-23-25	Upgrade	Leerink Partners	Market Perform → Outperform	$12
May-15-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$10
Sep-13-24	Downgrade	H.C. Wainwright	Buy → Neutral	$17 → $4
Sep-12-24	Downgrade	Stifel	Buy → Hold
Sep-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$15 → $4
Sep-12-24	Downgrade	Leerink Partners	Outperform → Market Perform	$4
Sep-12-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-24	Downgrade	BofA Securities	Neutral → Underperform	$10 → $2
Sep-09-24	Upgrade	BofA Securities	Underperform → Neutral	$5 → $10
May-20-24	Initiated	Cantor Fitzgerald	Overweight	$23
Mar-13-24	Initiated	RBC Capital Mkts	Outperform	$14

Show Previous Ratings

Jun-02-26 11:04PM	Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? (Stocktwits) -51.09%
09:43AM	Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls (The Fly)
08:08AM	Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug (BioPharma Dive)
07:53AM	This Biotech Stock Plunges 48%. Its Sickle Cell Drug Has 'No Viable Path Forward.' (Barrons.com)
Jun-01-26 05:50PM	FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk (Stocktwits) -7.23%
04:05PM	Loading…
04:05PM	Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review (GlobeNewswire)
May-08-26 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-28-26 03:02AM	Fulcrum Therapeutics Inc (FULC) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Apr-27-26 12:46PM	Fulcrum Therapeutics, Inc. Q1 2026 Earnings Call Summary (Moby)
11:08AM	Fulcrum Therapeutics Shares Climb After Q1 Earnings Outperform Expectations (InvestorsHub)
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 (GlobeNewswire)
06:55AM	Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors (GlobeNewswire)
Apr-20-26 08:00AM	Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET (GlobeNewswire)
Mar-19-26 08:00AM	MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease (GlobeNewswire)
Mar-06-26 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:30AM	Loading…
Mar-03-26 08:30AM	Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-25-26 10:27AM	Fulcrum Therapeutics move lower overdone, says Stifel (TipRanks)
Feb-24-26 08:05PM	Fulcrum Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby) -21.21%
11:47AM	Fulcrum Therapeutics Q4 Earnings Call Highlights (MarketBeat)
09:48AM	What's Going On With Fulcrum Therapeutics Stock Tuesday? (Benzinga)
07:01AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 (GlobeNewswire)
07:00AM	Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Feb-17-26 08:00AM	Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Feb-12-26 09:55AM	Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High? (Zacks)
Feb-06-26 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.03%
Jan-09-26 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-07-26 08:00AM	Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-25 09:55AM	Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet (Zacks) -5.42%
Dec-21-25 07:31AM	Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study (Insider Monkey)
Dec-10-25 07:48AM	Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.48%
04:01PM	Loading…
Dec-08-25 04:01PM	Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock (GlobeNewswire) +45.96% +12.39%
Dec-06-25 05:30PM	Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-05-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +45.96%
Dec-02-25 08:30AM	Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 (GlobeNewswire) -9.32%
Nov-20-25 12:33PM	AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results (Zacks)
Nov-19-25 04:20PM	Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged (Investor's Business Daily) +18.29%
Nov-07-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 09:45AM	Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls (The Fly)
Nov-03-25 04:45PM	Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting (GlobeNewswire) -7.21%
Oct-29-25 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025 (GlobeNewswire) -6.40%
Oct-22-25 08:54AM	Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET (GlobeNewswire) -6.80%
Oct-14-25 07:00AM	Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 (GlobeNewswire)
Oct-10-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.55%
Sep-12-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-25 08:00AM	Fulcrum Therapeutics to Present at Upcoming Investor Meetings (GlobeNewswire)
Aug-08-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-29-25 06:48AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 (GlobeNewswire)
06:45AM	Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Jul-28-25 04:01PM	Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease (GlobeNewswire)
Jul-11-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-25 01:17AM	Fulcrum Therapeutics, Inc. (FULC): A Bull Case Theory (Insider Monkey)
May-29-25 04:10PM	Fulcrum Therapeutics to Present at Upcoming Medical Meetings (GlobeNewswire)
08:30AM	Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-09-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.77%
May-08-25 04:05PM	Fulcrum Therapeutics to Participate in Upcoming May Conferences (GlobeNewswire) +6.71%
May-02-25 03:03AM	Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ... (GuruFocus.com) +28.31%
01:27AM	Q1 2025 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-01-25 01:55PM	Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript (Seeking Alpha) +13.77%
07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025 (GlobeNewswire)
Apr-24-25 08:00AM	Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET (GlobeNewswire)
Apr-11-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.55%
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-04-25 04:05PM	Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-26-25 02:04AM	Fulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) -10.27%
01:28AM	Q4 2024 Fulcrum Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 (GlobeNewswire)
01:52AM	Earnings To Watch: Fulcrum Therapeutics Inc (FULC) Reports Q4 2024 Result (GuruFocus.com)
Feb-18-25 04:05PM	Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET (GlobeNewswire)
Feb-07-25 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-06-25 04:05PM	Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-28-24 12:00PM	Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why (Zacks)
Nov-26-24 04:05PM	Fulcrum Therapeutics to Participate in Upcoming December Conferences (GlobeNewswire) +11.27%
Nov-14-24 02:07AM	Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ... (GuruFocus.com) -6.74%
Nov-13-24 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2024 (GlobeNewswire)
Nov-12-24 04:05PM	Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference (GlobeNewswire)
Nov-06-24 08:00AM	Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET (GlobeNewswire)
Oct-18-24 08:00AM	Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up (Investor's Business Daily)
Oct-11-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.42%
Oct-09-24 03:30PM	Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ... (GuruFocus.com)
Oct-07-24 03:02PM	FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares (GuruFocus.com) -6.54%
Oct-04-24 09:35AM	Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround (Zacks)
Sep-17-24 01:30AM	RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares (GuruFocus.com) +9.75%
Sep-16-24 09:35AM	Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-13-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.56%
Sep-12-24 11:32AM	Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial (Benzinga) -61.13%
08:10AM	Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test (BioPharma Dive)
06:55AM	Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) (GlobeNewswire)
Sep-09-24 02:28PM	Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease (Benzinga)
Aug-27-24 04:05PM	Fulcrum Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire) -9.09%
Aug-23-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.22%
Aug-21-24 09:55AM	Wall Street Analysts Believe Fulcrum Therapeutics (FULC) Could Rally 71.02%: Here's is How to Trade (Zacks)
Aug-19-24 07:00AM	Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer (GlobeNewswire)
Aug-09-24 04:30PM	Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-24 12:00PM	Fulcrum Therapeutics (FULC) Upgraded to Strong Buy: Here's What You Should Know (Zacks) -11.41%
12:00PM	Fulcrum Therapeutics, Inc. (FULC) Is Up 7.55% in One Week: What You Should Know (Zacks)
09:55AM	Does Fulcrum Therapeutics (FULC) Have the Potential to Rally 68.69% as Wall Street Analysts Expect? (Zacks)
Jul-31-24 07:00AM	Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024 (GlobeNewswire) +10.34%
Jul-24-24 08:00AM	Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET (GlobeNewswire)
Jun-12-24 08:00AM	Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress (GlobeNewswire)

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

CEOMr. Alexander C. Sapir

Chief Legal OfficerMr. Curtis G. Oltmans J.D.

Ph.D.Dr. Bradley E. Bernstein M.D.

FounderDr. Michael R. Green

Ph.D.Dr. Rudolf Jaenisch M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ezekowitz Alan	Director	Jun 26 '26	Sale	3.65	18,000	65,614	10,927	Jun 30 04:30 PM
ALAN EZEKOWITZ	Director	Jun 26 '26	Proposed Sale	3.61	18,000	64,980		Jun 26 04:26 PM
Gould Robert J	Director	Feb 02 '26	Sale	10.72	15,000	160,857	454,864	Feb 04 04:10 PM
Gould Robert J	Director	Jan 02 '26	Sale	11.87	15,000	178,089	469,864	Jan 06 04:30 PM
Oltmans Curtis Gale	Chief Legal Officer	Dec 15 '25	Sale	12.92	3,452	44,600	10,252	Dec 17 04:10 PM
CURTIS G OLTMANS	Officer	Dec 15 '25	Proposed Sale	13.00	3,452	44,876		Dec 15 04:32 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Dec 08 '25	Sale	13.98	4,175,139	58,377,021	6,053,960	Dec 10 04:42 PM
RA Capital Healthcare Fund LP	10% Owner	Dec 08 '25	Proposed Sale	12.99	4,175,139	54,235,056		Dec 08 05:40 PM
Gould Robert J	Director	Nov 19 '25	Sale	11.03	15,000	165,495	484,864	Nov 21 04:15 PM
ROBERT J GOULD	Director	Nov 19 '25	Proposed Sale	9.73	45,000	437,850		Nov 19 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FULC

Fulcrum Therapeutics Inc

Upgrade your Finviz experience